session highlights: idh inhibitors, salvage regimens, and other novel developments in aml
Published 1 year ago • 124 plays • Length 2:22Download video MP4
Download video MP3
Similar videos
-
1:25
idh inhibitors for aml: highlights from ash 2018
-
1:32
idh inhibitors for aml and mds
-
0:54
idh inhibitors and the evolving aml treatment paradigm
-
2:08
the impact of idh mutations on the outcomes of patients with aml & inhibitors under investigation
-
16:35
key highlights in mpns at ash 2023: novel agents & combinations, ongoing clinical trials, and more
-
1:23
decitabine, venetoclax, and idh inhibitor in idh-mutated aml
-
4:05
al amyloidosis special session highlights: therapeutic advances and ongoing trials in the field
-
0:59
idh inhibitors in aml
-
3:14
updates on idh inhibition in aml
-
1:51
idh1/2 inhibitors for upfront aml therapy and transfusion independence
-
2:57
targeting idh mutations for the treatment of aml
-
1:18
beat aml master sub-study: enasidenib and response-driven addition of azacitidine in idh2m aml
-
1:07
advancements in combination strategies with jak inhibitors for myelofibrosis
-
3:20
safety run-in of a phase ii trial of cpx-351 plus pomalidomide in aml with mds-related changes
-
1:27
the safety and efficacy of grb2 inhibition with bp1001 in aml
-
1:45
ham-ven as salvage treatment for r/r aml: results from the sal-relax trial
-
1:37
a phase ii trial evaluating e7820 in patients with aml with splicing factor mutations
-
2:06
ims session highlights: high-risk myeloma